

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
 (Not for submission under 37 CFR 1.99)

Application Number	10577167
Filing Date	2007-08-05
First Named Inventor	David M. Briscoe
Art Unit	1644
Examiner Name	
Attorney Docket Number	701039-053522

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10577167
Filing Date	2007-08-05
First Named Inventor	David M. Briscoe
Art Unit	1644
Examiner Name	
Attorney Docket Number	701039-053522

1	SIDKY, Y.A. and AUERBACH, R. 1975. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. <i>J Exp Med</i> 141:1084-1100.	<input type="checkbox"/>
2	AUERBACH, R. and SIDKY, Y.A. 1979. Nature of the stimulus leading to lymphocyte-induced angiogenesis. <i>J Immunol</i> 123:751-754.	<input type="checkbox"/>
3	Chapter 3, Inflammation and repair. In: Cotran RS, Kumar V, Robbins SL, editors. <i>Pathologic Basis of Disease</i> . WB Saunders, Philadelphia. 51-92, 1994.	<input type="checkbox"/>
4	MOULTON, K.S., et al. 1999. Angiogenesis in the huPBL-SCID model of human transplant rejection. <i>Transplantation</i> 67:1626-1631.	<input type="checkbox"/>
5	LEUNG, D.W., et al. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. <i>Science</i> 246:1306-1309.	<input type="checkbox"/>
6	FOLKMAN, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. <i>Nat Med</i> 1. 27-31.	<input type="checkbox"/>
7	FERRARA, N. and DAVIS-SMYTH, T. 1997. The biology of vascular endothelial growth factor. <i>Endocr Rev</i> 18:4-25.	<input type="checkbox"/>
8	GERBER, H.P., et al. 1998. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. <i>J Biol Chem</i> 273:13313-13316.	<input type="checkbox"/>
9	MELDER, R.J., et al. 1996. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. <i>Nat Med</i> 2:992-997.	<input type="checkbox"/>
10	KIM, I., et al. 2001. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. <i>J Biol Chem</i> 276:7614-7620.	<input type="checkbox"/>
11	BARLEON, B., et al. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. <i>Blood</i> 87:3336-3343.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10577167
Filing Date	2007-08-05
First Named Inventor	David M. Briscoe
Art Unit	1644
Examiner Name	
Attorney Docket Number	701039-053522

12	MELTER, M., et al. 2000. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. <i>Blood</i> 96:3801-3808.	<input type="checkbox"/>
13	FREEMAN, M.R., et al. 1995. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. <i>Cancer Res</i> 55:4140-4145.	<input type="checkbox"/>
14	SOKER, S., et al. 1996. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. <i>J Biol Chem</i> 271:5761-5767.	<input type="checkbox"/>
15	CLAUSS, M., et al. 1996. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. <i>J Biol Chem</i> 271:17629-17634.	<input type="checkbox"/>
16	SHWEIKI, D., et al. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. <i>Nature</i> 359:843-845.	<input type="checkbox"/>
17	SATO, K., et al. 1995. Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and fit mRNA expression in the rat thyroid in vivo. <i>J Clin Invest</i> 96:1295-1302.	<input type="checkbox"/>
18	SHWEIKI, D., et al. 1995. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. <i>Proc Natl Acad Sci U S A</i> 92:768-772.	<input type="checkbox"/>
19	WILLIAMS, B., et al. 1995. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. <i>Hypertension</i> 25:913-917.	<input type="checkbox"/>
20	WILLIAMS, B., et al. 1995. Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro. <i>Clin Sci</i> 88:141-147.	<input type="checkbox"/>
21	REINDERS, M. E., et al. Proangiogenic function of CD40 ligand-CD40 interactions. <i>J Immunol</i> 171(3), 1534-41. 2003.	<input type="checkbox"/>
22	REINDERS, M. E. J., et al. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. <i>Transplantation</i> 76(1), 224-30. 2003.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10577167
Filing Date	2007-08-05
First Named Inventor	David M. Briscoe
Art Unit	1644
Examiner Name	
Attorney Docket Number	701039-053522

23	SHAHBAZI, M., et al. 2002. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. <i>J Am Soc Nephrol</i> 13:260-264.	<input type="checkbox"/>
24	PILMORE, H.L., et al. 1999. Vascular endothelial growth factor expression in human chronic renal allograft rejection. <i>Transplantation</i> 67:929-933.	<input type="checkbox"/>
25	TORRY, R.J., et al. 1995. Vascular endothelial growth factor expression in transplanted human hearts. <i>Transplantation</i> 60:1451-1457.	<input type="checkbox"/>
26	KIM, K.J., et al. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> . <i>Nature</i> 362:841-4.	<input type="checkbox"/>
27	PRESTA, L. G., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. <i>Cancer Res</i> 57(20), 4593-9, 1997.	<input type="checkbox"/>
28	KHAN, I.A., et al. 2000. IP-10 is critical for effector T cell trafficking and host survival in <i>Toxoplasma gondii</i> infection. <i>Immunity</i> 12:483-494.	<input type="checkbox"/>
29	O'REILLY, M.S., et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. <i>Cell</i> 88:277-85.	<input type="checkbox"/>
30	BOEHM, T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. <i>Nature</i> 390, 404-7, 1997.	<input type="checkbox"/>
31	BERGERS, G., et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. <i>Science</i> 284, 808-12, 1999.	<input type="checkbox"/>
32	TILTON, R.G., et al. 1997. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. <i>J Clin Invest</i> 99:2192-2202.	<input type="checkbox"/>
33	BASU, S., et al. 2001. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. <i>Nat Med</i> 7:569-574.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10577167
Filing Date	2007-08-05
First Named Inventor	David M. Briscoe
Art Unit	1644
Examiner Name	
Attorney Docket Number	701039-053522

34	WALTER, D.H., et al. 1996. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. <i>Lab Invest</i> 74:546-556.	<input type="checkbox"/>
35	DUFOUR, J.H., et al. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. <i>J Immunol</i> 168:3195-3204.	<input type="checkbox"/>
36	BRISCOE, D.M., et al. 1999. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. <i>Transplantation</i> 67:1590-1599.	<input type="checkbox"/>
37	CORRY, R.J., et al. 1973. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. <i>Transplantation</i> 16:343-350.	<input type="checkbox"/>
38	LU, J., et al. 2000. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. <i>J Immunol</i> 164:5922-5927.	<input type="checkbox"/>
39	HANCOCK, W.W., et al. 2001. Donor-derived IP-10 initiates development of acute allograft rejection. <i>J Exp Med</i> 193:975-980.	<input type="checkbox"/>
40	YAMADA, A., et al. 2001. CD28-independent costimulation of T cells in alloimmune responses. <i>J Immunol</i> 167:140-146.	<input type="checkbox"/>
41	GIMBRONE, M.A. 1976. Culture of vascular endothelium. <i>Prog Hemost Thromb</i> 3:1-28.	<input type="checkbox"/>
42	MARELLI-BERG, F.M., 2000. Isolation of endothelial cells from murine tissue. <i>J Immunol Methods</i> 244:205-215.	<input type="checkbox"/>
43	DENTON, M.D., et al. 1999. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4+ T cell alloactivation. <i>J Exp Med</i> 190:555-566.	<input type="checkbox"/>
44	MURRAY, A.G., et al. 1994. Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. <i>Proc Natl Acad Sci U S A</i> 91:9146-9150.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10577167
Filing Date	2007-08-05
First Named Inventor	David M. Briscoe
Art Unit	1644
Examiner Name	
Attorney Docket Number	701039-053522

45

LUSTER, A.D., et al. 1987. Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells. Proc Natl Acad Sci U S A 84:2868-2871.



If you wish to add additional non-patent literature document citation information please click the Add button

**Add**

**EXAMINER SIGNATURE**

Examiner Signature	/Ronald Schwadron/	Date Considered	09/17/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.